These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 12431611)
21. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients? Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery. Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of oral cyclosporine microemulsion formulation (Neoral) in children awaiting renal transplantation. Gusmano R; Basile GC; Perfumo F; Ginevri F; Verrina E; Famularo L; Corbetta G Transplant Proc; 1998 Aug; 30(5):1985-7. PubMed ID: 9723362 [No Abstract] [Full Text] [Related]
24. Pharmacokinetic comparison of two cyclosporine A formulations, SangCya (Sang-35) and Neoral, in stable adult liver transplant recipients. Fisher RA; Pan SH; Rossi SJ; Schroeder TJ; Irish WD; Canafax DM; Lopez RR Transplant Proc; 1999; 31(1-2):394-5. PubMed ID: 10083157 [No Abstract] [Full Text] [Related]
25. Importance of cyclosporine pharmacokinetics to clinical outcomes after liver transplantation. Canadian Liver Transplant Study Group. Transplant Proc; 1998 Aug; 30(5):1826-7. PubMed ID: 9723297 [No Abstract] [Full Text] [Related]
26. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Noble S; Markham A Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033 [TBL] [Abstract][Full Text] [Related]
27. Improvement of correlation between oral dose of cyclosporine and cyclosporinemia after substitution of cyclosporine standard presentation by cyclosporine microemulsion one, in 1345 patients with kidney transplantation. Spanish Sandimmune Neoral Conversion Group. Gentil Govantes MA; Gómez Ullate P; Errasti P; Fernández Fresnedo G; Capdevila L; Sanz Guajardo A; Cubero JJ Transplant Proc; 1998 Aug; 30(5):1658-9. PubMed ID: 9723231 [No Abstract] [Full Text] [Related]
28. Early use and oral absorption of cyclosporine neoral after liver transplantation. Kattner A; Ringe B; Haller GW; Kirchner G; Sewing KF; Winkler M Transplant Proc; 1998 Jun; 30(4):1422-3. PubMed ID: 9636576 [No Abstract] [Full Text] [Related]
29. Equivalence of cyclosporine blood level assays in patients receiving cyclosporine microemulsion or cyclosporine. The Sandoz Neoral Study Group N103. Pescovitz MD; Wong RL; Choc MG; Chang CT Clin Transplant; 1997 Oct; 11(5 Pt 1):442-5. PubMed ID: 9361938 [TBL] [Abstract][Full Text] [Related]
30. Absorption characteristics of a microemulsion formulation of cyclosporine in de novo pediatric liver transplant recipients. Dunn SP; Cooney GF; Kulinsky A; Falkenstein K; Pierson A; Elder CA; Meligeni J Transplantation; 1995 Dec; 60(12):1438-42. PubMed ID: 8545871 [TBL] [Abstract][Full Text] [Related]
36. Comparison of cyclosporine absorption profiles over a 12-month period in stable pediatric renal transplant recipients. Wigger M; Drückler E; Muscheites J; Stolpe HJ; Kundt G; Wacke R Transplant Proc; 2003 Jun; 35(4):1300-3. PubMed ID: 12826143 [TBL] [Abstract][Full Text] [Related]
37. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Kovarik JM; Mueller EA; Richard F; Niese D; Halloran PF; Jeffery J; Paul LC; Keown PA Transplantation; 1996 Sep; 62(6):759-63. PubMed ID: 8824473 [TBL] [Abstract][Full Text] [Related]